Entrada Therapeutics Inc (TRDA)

Currency in USD
5.19
-0.11(-2.08%)
Closed·
After Hours
5.190.00(0.00%)
·
TRDA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TRDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.055.47
52 wk Range
4.9821.79
Key Statistics
Prev. Close
5.3
Open
5.35
Day's Range
5.05-5.47
52 wk Range
4.98-21.79
Volume
308.3K
Average Volume (3m)
167.66K
1-Year Change
-61.62%
Book Value / Share
10.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TRDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.50
Upside
+294.99%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Entrada Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Entrada Therapeutics Inc Company Profile

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company’s EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Compare TRDA to Peers and Sector

Metrics to compare
TRDA
Peers
Sector
Relationship
P/E Ratio
−2.5x−3.6x−0.5x
PEG Ratio
0.02−0.070.00
Price/Book
0.5x2.1x2.6x
Price / LTM Sales
2.3x6.7x3.3x
Upside (Analyst Target)
255.8%67.9%43.4%
Fair Value Upside
Unlock2.5%7.1%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.50
(+294.99% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-1.04 / -0.82
Revenue / Forecast
2.00M / 9.65M
EPS Revisions
Last 90 days

TRDA Income Statement

People Also Watch

18.23
SRPT
+1.50%
13.73
KROS
+2.77%
0.408
CLSD
+6.40%
264.21
BIO
-0.39%
11.97
CDNA
-0.83%

FAQ

What Stock Exchange Does Entrada Therapeutics Trade On?

Entrada Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Entrada Therapeutics?

The stock symbol for Entrada Therapeutics is "TRDA."

What Is the Entrada Therapeutics Market Cap?

As of today, Entrada Therapeutics market cap is 188.43M.

What Is Entrada Therapeutics's Earnings Per Share (TTM)?

The Entrada Therapeutics EPS (TTM) is -1.79.

When Is the Next Entrada Therapeutics Earnings Date?

Entrada Therapeutics will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is TRDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Entrada Therapeutics Stock Split?

Entrada Therapeutics has split 0 times.

How Many Employees Does Entrada Therapeutics Have?

Entrada Therapeutics has 183 employees.

What is the current trading status of Entrada Therapeutics (TRDA)?

As of 08 Aug 2025, Entrada Therapeutics (TRDA) is trading at a price of 5.19, with a previous close of 5.30. The stock has fluctuated within a day range of 5.05 to 5.47, while its 52-week range spans from 4.98 to 21.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.